Notable studies showing greater benefit in patients with ABC (or non-GCB) COO DLBCL receiving polatuzumab
| Variable . | Tilly et al1 . | Morschhauser et al10 . | Sehn et al11 and Sehn et al12 . | Terui et al13 . | Liu et al14 . | Segman et al15,16 . | Tsai et al17 and Wang et al18 . |
|---|---|---|---|---|---|---|---|
| Trial identifier | POLARIX (NCT03274492) | ROMULUS (NCT01691898) | GO29365 (NCT02257567) | JapicCTI-184048 | N/A | N/A | N/A |
| Study design | Prospective | Prospective | Prospective | Prospective | Retrospective | Retrospective | Retrospective |
| Location | International | International | International | Japan | China | Israel | Taiwan |
| Clinical setting | Frontline DLBCL | Rel/ref DLBCL ≥1 prior therapies | Rel/ref DLBCL ≥1 prior therapies Ineligible for ASCT | Rel/ref DLBCL ≥1 prior therapies Ineligible for ASCT | Rel/ref DLBCL ≥2 prior therapies | Rel/ref DLBCL ≥2 prior therapies | Rel/ref DLBCL ≥2 prior therapies |
| Treatment | Pola-R-CHP vs R-CHOP | Polatuzumab + R | Polatuzumab + BR | Polatuzumab + BR | Polatuzumab + BR or R | Polatuzumab + B ± R | Polatuzumab + physician’s choice chemotherapy |
| Sample size∗ | Pola-R-CHP: 440 R-CHOP: 439 | 23 | 32 | 35 | 28 | 34 | 40 |
| ORR in ABC (or non GCB) vs GCB, % | 2-y PFS† ABC: Pola-R-CHP: 83.9 vs R-CHOP: 58.8 GCB: Pola-R-CHP: 75.1 vs R-CHOP: 76.9 | 83.3 vs 45.5 | 58.8 vs 33.3 | 46.2 vs 7.1 (CRR) | 70.6 vs 63.6 | 80 vs 43 | 65.0 vs 31.3 |
| COO method | NanoString Lymph2Cx | Fluidigm targeted gene expression profiling assay | NanoString Lymph2Cx and Hans algorithm | NanoString Lymph2Cx | Hans algorithm | Hans algorithm | Hans algorithm |
| Variable . | Tilly et al1 . | Morschhauser et al10 . | Sehn et al11 and Sehn et al12 . | Terui et al13 . | Liu et al14 . | Segman et al15,16 . | Tsai et al17 and Wang et al18 . |
|---|---|---|---|---|---|---|---|
| Trial identifier | POLARIX (NCT03274492) | ROMULUS (NCT01691898) | GO29365 (NCT02257567) | JapicCTI-184048 | N/A | N/A | N/A |
| Study design | Prospective | Prospective | Prospective | Prospective | Retrospective | Retrospective | Retrospective |
| Location | International | International | International | Japan | China | Israel | Taiwan |
| Clinical setting | Frontline DLBCL | Rel/ref DLBCL ≥1 prior therapies | Rel/ref DLBCL ≥1 prior therapies Ineligible for ASCT | Rel/ref DLBCL ≥1 prior therapies Ineligible for ASCT | Rel/ref DLBCL ≥2 prior therapies | Rel/ref DLBCL ≥2 prior therapies | Rel/ref DLBCL ≥2 prior therapies |
| Treatment | Pola-R-CHP vs R-CHOP | Polatuzumab + R | Polatuzumab + BR | Polatuzumab + BR | Polatuzumab + BR or R | Polatuzumab + B ± R | Polatuzumab + physician’s choice chemotherapy |
| Sample size∗ | Pola-R-CHP: 440 R-CHOP: 439 | 23 | 32 | 35 | 28 | 34 | 40 |
| ORR in ABC (or non GCB) vs GCB, % | 2-y PFS† ABC: Pola-R-CHP: 83.9 vs R-CHOP: 58.8 GCB: Pola-R-CHP: 75.1 vs R-CHOP: 76.9 | 83.3 vs 45.5 | 58.8 vs 33.3 | 46.2 vs 7.1 (CRR) | 70.6 vs 63.6 | 80 vs 43 | 65.0 vs 31.3 |
| COO method | NanoString Lymph2Cx | Fluidigm targeted gene expression profiling assay | NanoString Lymph2Cx and Hans algorithm | NanoString Lymph2Cx | Hans algorithm | Hans algorithm | Hans algorithm |
ASCT, autologous stem cell transplant; B, bendamustine; CRR, complete response rate; N/A, not applicable; ORR, overall response rate; R, rituximab; Rel/ref, relapsed/refractory.
Sample size refers to the number of patients who received polatuzumab, with the exception of POLARIX, where both arms are reported.
POLARIX did not report ORR by COO; thus, PFS is listed.